Point72 (DIFC)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Point72 (DIFC)’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$101K	Buy	3,367 +1,191	+55%	+$35.7K	0.01%	575
2025 Q2	$79.1K	Sell	2,176 -19,269	-90%	-$695K	﹤0.01%	963
2025 Q1	$777K	Buy	21,445 +2,825	+15%	+$118K	0.03%	533
2024 Q4	$783K	Buy	18,620 +4,103	+28%	+$204K	0.03%	528
2024 Q3	$806K	Buy	14,517 +11,848	+444%	+$604K	0.03%	533
2024 Q2	$110K	Sell	2,669 -7,383	-73%	-$315K	﹤0.01%	952
2024 Q1	$469K	Buy	+10,052	New	+$474K	0.01%	767

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Point72 (DIFC)'s RARE Position: Q3 2025 in Review

Point72 (DIFC) increased its Ultragenyx Pharmaceutical (RARE) stake by 55% in Q3 2025, buying an estimated $35.7K and bringing the position to 3,367 shares worth $101K. The position accounts for 0.01% of the portfolio, ranked #575.

Point72 (DIFC) first reported a position in RARE in Q1 2024 and has held it in 7 quarters since. The position peaked at $806K in Q3 2024. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

Point72 (DIFC) held 3,367 shares of Ultragenyx Pharmaceutical worth $101K as of Q3 2025.
Point72 (DIFC) bought 1,191 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $35.7K.
Ultragenyx Pharmaceutical made up 0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #575 holding.
Point72 (DIFC) first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 7 quarters since.
Point72 (DIFC)'s Ultragenyx Pharmaceutical position peaked at $806K in Q3 2024.
302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.